CONSOLIDATED HIV STRATEGIC INFORMATION GUIDELINES

DRIVING IMPACT THROUGH PROGRAMME MONITORING AND MANAGEMENT

WEB ANNEX A
MAPPING OF 2020 INDICATORS TO 2015 GUIDELINE INDICATORS

APRIL 2020

The text of the Consolidated strategic information guidelines, April 2020, is available online at: https://apps.who.int/iris/bitstream/handle/10665/331697/9789240000735-eng.pdf
### WEB ANNEX A  MAPPING OF 2020 INDICATORS TO 2015 GUIDELINE INDICATORS

<table>
<thead>
<tr>
<th>2015 national indicators by reference number &amp; short name</th>
<th>Status</th>
<th>Corresponding 2020 indicator reference number &amp; short name</th>
</tr>
</thead>
<tbody>
<tr>
<td>NEEDS.1 People living with HIV</td>
<td>Retained</td>
<td>BI.1 People living with HIV</td>
</tr>
<tr>
<td>NEEDS.2 Key populations (size)</td>
<td></td>
<td>(Included in KP.1 Coverage of HIV prevention (KP))</td>
</tr>
<tr>
<td>NEEDS.3 Coinfection</td>
<td>Retired</td>
<td></td>
</tr>
<tr>
<td>NEEDS.4 ART eligibility</td>
<td>Retired</td>
<td></td>
</tr>
<tr>
<td>NEEDS.5 HIV-positive pregnant women</td>
<td></td>
<td>(Included in BI.4 Final MTCT rate)</td>
</tr>
<tr>
<td>NEEDS.7 Key population experience with discrimination</td>
<td>Retired</td>
<td></td>
</tr>
<tr>
<td>KPOP.1/HITS.7 HIV testing coverage of key populations</td>
<td>Modified</td>
<td>Additional indicator TL.8 Coverage of HIV testing in prevention services</td>
</tr>
<tr>
<td>KPOP.2 Needle–syringe distribution</td>
<td>Retained</td>
<td>KP.2 Needles and syringes distributed</td>
</tr>
<tr>
<td>KPOP.3 Key population ART coverage</td>
<td>Modified</td>
<td>AV.1 PLHIV on ART – with KP disaggregation</td>
</tr>
<tr>
<td>PREV.1.a Condom use among SW</td>
<td>Modified</td>
<td>Consolidated into one indicator with specific definitions for each group: PR.1 Condom use (KP &amp; Gen pop)</td>
</tr>
<tr>
<td>PREV.1.b Condom use among MSM</td>
<td>Modified</td>
<td></td>
</tr>
<tr>
<td>PREV.1.c Condom use among PWID</td>
<td>Modified</td>
<td></td>
</tr>
<tr>
<td>PREV.1.d Condom use in general population</td>
<td>Modified</td>
<td></td>
</tr>
<tr>
<td>PREV.5 Facility-level injection safety</td>
<td>Retained</td>
<td>DfI.1 Facility-level injection safety</td>
</tr>
<tr>
<td>PREV.7 Facility-level blood safety</td>
<td>Modified</td>
<td>DfB.1 Facility-level blood safety</td>
</tr>
<tr>
<td>PREV.9 ANC syphilis screening coverage</td>
<td>Retained</td>
<td>ST.1 Syphilis screening coverage (in ANC)</td>
</tr>
<tr>
<td>PREV.10 Syphilis treatment</td>
<td>Retained</td>
<td>ST.2 Syphilis treatment coverage (in ANC)</td>
</tr>
<tr>
<td>HTS.1 People living with HIV diagnosed</td>
<td>Modified</td>
<td>TL.1 PLHIV who know their HIV status</td>
</tr>
<tr>
<td>HTS.2 HTS scale-up</td>
<td>Modified</td>
<td>TL.2 HTS testing volume and positivity</td>
</tr>
<tr>
<td>HTS.3 HTS retest</td>
<td>Retained</td>
<td>Additional indicator TL.8 HIV Retesting to verify diagnosis at ART initiation</td>
</tr>
<tr>
<td>HTS.4/MTCT.1 PMTCT testing coverage</td>
<td>Retained</td>
<td>Additional indicator MT.8 HIV testing among pregnant women</td>
</tr>
<tr>
<td>HTS.5/MTCT.6 Coverage of early infant diagnosis</td>
<td>Retained</td>
<td>VT.2 EID coverage</td>
</tr>
<tr>
<td>LINK.1 Linkage to care</td>
<td>Modified</td>
<td>TL.3 Linkage to ART</td>
</tr>
<tr>
<td>LINK.2 HIV care coverage</td>
<td>Retired</td>
<td></td>
</tr>
<tr>
<td>LINK.3 Enrolment in care</td>
<td>Retired</td>
<td></td>
</tr>
<tr>
<td>LINK.4/MTCT.10 Unmet need for family planning</td>
<td>Retired</td>
<td></td>
</tr>
<tr>
<td>LINK.5 TB screening coverage in HIV care</td>
<td>Modified</td>
<td>DfT.1 TB screening coverage among new ART patients</td>
</tr>
<tr>
<td>LINK.12 TB prevalence in HIV care</td>
<td>Modified</td>
<td>TB.4 PLHIV with active TB disease</td>
</tr>
<tr>
<td>LINK.17 IPT/LTBI treatment coverage</td>
<td>Modified</td>
<td>TB.1 TPT initiation</td>
</tr>
<tr>
<td>LINK.27 Hepatitis B screening</td>
<td>Retired</td>
<td></td>
</tr>
<tr>
<td>LINK.28 Hepatitis C screening</td>
<td>Retained</td>
<td>DfH1. HCV screening coverage</td>
</tr>
<tr>
<td>2015 national indicators by reference number &amp; short name</td>
<td>Status</td>
<td>Corresponding 2020 indicator reference number &amp; short name</td>
</tr>
<tr>
<td>----------------------------------------------------------</td>
<td>--------------</td>
<td>-----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>ART.1 New ART patients</td>
<td>Retained</td>
<td>AV.4 New ART patients</td>
</tr>
<tr>
<td>ART.2 ART coverage 1</td>
<td>Retired</td>
<td></td>
</tr>
<tr>
<td>ART.3 ART coverage 2</td>
<td>Modified</td>
<td>AV.1 PLHIV on ART</td>
</tr>
<tr>
<td>ART.4 Late ART initiation</td>
<td>Modified</td>
<td>AV.5 Late ART initiation</td>
</tr>
<tr>
<td>ART.5 ART retention</td>
<td>Modified</td>
<td>AV.2 Total attrition from ART</td>
</tr>
<tr>
<td>ART.6 Medium-term ART outcomes</td>
<td>Retired</td>
<td></td>
</tr>
<tr>
<td>ART.7 ART adherence proxy</td>
<td>Retained</td>
<td>Additional indicator AV.11 ART adherence proxy (ARV refills)</td>
</tr>
<tr>
<td>ART.8/VLS.2 Viral load testing coverage</td>
<td>Modified</td>
<td>AV.6 VL testing coverage</td>
</tr>
<tr>
<td>ART.9/ART/15/VLS.1 Viral load suppression at 12 months</td>
<td>Retired</td>
<td></td>
</tr>
<tr>
<td>ART.10 ARV stock-out</td>
<td>Retained</td>
<td>Additional indicator AV.10 ARV medicine stock-out</td>
</tr>
<tr>
<td>ART.11 ART survival</td>
<td>Retired</td>
<td></td>
</tr>
<tr>
<td>ART.12 Toxicity prevalence</td>
<td>Retained</td>
<td>AV.9 ARV toxicity prevalence</td>
</tr>
<tr>
<td>VLS.3 Viral suppression</td>
<td>Modified</td>
<td>AV.3 PLHIV who have suppressed VL</td>
</tr>
<tr>
<td>VLS.4 Viral load monitoring</td>
<td>Retired</td>
<td></td>
</tr>
<tr>
<td>MTCT.2 PMTCT ART coverage</td>
<td>Modified</td>
<td>VT.4 ART coverage in pregnant women</td>
</tr>
<tr>
<td>MTCT.3 ART retention</td>
<td>Modified</td>
<td>Additional indicator MT.12 ART retention PMTCT</td>
</tr>
<tr>
<td>MTCT.4 Coverage of infant ARV prophylaxis</td>
<td>Retained</td>
<td>VT.3 Infant ARV prophylaxis coverage</td>
</tr>
<tr>
<td>MTCT.5 ARV coverage for breastfeeding patients</td>
<td>Modified</td>
<td>VT.5 ART coverage in breastfeeding mothers</td>
</tr>
<tr>
<td>MTCT.7 Final MTCT transmission rate</td>
<td>Retained</td>
<td>Bl.4 Final MTCT rate</td>
</tr>
<tr>
<td>MTCT.8 Final outcome status</td>
<td>Retained</td>
<td>VT.6 Final outcome of PMTCT</td>
</tr>
<tr>
<td>MTCT.9 Co-trimoxazole prophylaxis coverage</td>
<td>Retained</td>
<td>Additional indicator MT.13 CTX coverage exposed infants</td>
</tr>
<tr>
<td>IMP.1 AIDS-related deaths</td>
<td>Retained</td>
<td>Bl.5 AIDS mortality</td>
</tr>
<tr>
<td>IMP.2 HIV incidence</td>
<td>Retained</td>
<td>Bl.3 New HIV infections (per 1000 population)</td>
</tr>
<tr>
<td>IMP.6 Equitable access to ART</td>
<td>Retired</td>
<td></td>
</tr>
</tbody>
</table>
2015 indicators that were not reviewed or modified

TB-side TB/HIV indicators –
- LINK.13 HIV prevalence among TB patients
- LINK.14 Mortality among HIV-positive TB patients
- LINK.15/HTS.6 HIV testing among TB patients
- LINK.16 ART coverage during TB treatment

HIVDR survey-based indicators –
- ART.14 HIVDR prevalence at ART initiation

Health systems indicators –
- RES.1 Service availability
- RES.12 Availability
- RES.13 Quality control of ARV medicines
- RES.31 Domestic public funding on HIV
- RES.33 HIV spending on health programmes
- RES.35 Country progress in domestic funding
- RES.36 Domestic private expenditure
- RES.37 Unit cost of HIV interventions
- NEEDS.6 General stigma